S&P Rebounds After 2 Days of Losses
The S&P 500 rose Wednesday, led by tech, as Nvidia reached a major milestone and investors monitored the latest tariff updates from President Donald Trump.The Dow Jones Industrials rebounded 66.08 points to 44,306.84.The much-broader index revived 16.66 points to 6,242.18.The NASDAQ Composite barreled ahead 104.68 points, or 1%, to 20,523.14.Nvidia shares traded $3.26, or 2%, higher, to $163.26, making it the first company to reach a market capitalization of $4 trillion. Other major tech names also rose, including Meta Platforms, Microsoft and Alphabet.On Wednesday, Trump sent letters dictating new U.S. tariff rates on goods from at least six more countries, including the Philippines and Iraq. This comes after Trump posted letters setting new duties earlier this week to the leaders of 14 other countries, including South Korea and Japan.Those moves came as traders seemingly shrugged off the latest tariff-related headlines of the week.In addition to watching further tariff policy developments on Wednesday, traders will be monitoring the release of the Federal Open Market Committee’s minutes from its last meeting.Prices for the 10-year treasury gained, raising yields to 4.37% from Tuesday’s 4.41%. Treasury prices and yields move in opposite directions. Oil prices recovered 20 cents to $68.53 U.S. a barrel. Gold prices were unchanged at $3,316.90 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


